Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
RESEARCH TOOLSreports
Holding ZNTL?
Track your performance easily
ZNTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.27 - $29.03
Previous Close$3.97
Volume895.05K
Average Volume (3M)1.41M
Market Cap
$281.92M
Enterprise Value$286.92M
Total Cash (Recent Filing)$37.62M
Total Debt (Recent Filing)$42.62M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 07, 2024EPS Estimate
-$0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding71,013,233
10 Day Avg. Volume4,002,730
30 Day Avg. Volume1,405,795
Standard Deviation0.20
R-Squared0.20
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.77
Price to Sales (P/S)8.32
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.07
Enterprise Value/Gross Profit318.80
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$10.70Price Target Upside168.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Zentalis Pharmaceuticals News
PremiumCompany Announcements
Zentalis Pharmaceuticals Announces New Leadership and Strategy Shift
PremiumCompany Announcements
Zentalis Pharmaceuticals Advances with FDA Approval and Upcoming DataBulls Say, Bears Say
Bulls Say
Clinical TrialsAzenosertib continues to be evaluated in over 10 ongoing and planned clinical trials, both as an independent therapeutic approach and in combination with established scientific rationales, targeting various tumor types.
Financial PositionThe company reported $489mn in cash and cash equivalents, projecting a runway into mid-2026, ensuring a strong financial position to achieve near-term readouts.
Patient EnrollmentEnrollment across azenosertib monotherapy studies has accelerated over the past several quarters, highlighting increasing interest among patients/physicians.
Bears Say
Clinical HoldThe FDA placed a partial clinical hold on three azenosertib monotherapy studies following two recent deaths due to presumed sepsis.
Management IssuesManagement's execution and communication issues along with the clinical hold make it less confident that azeno will be materially differentiated.
Safety ConcernsPartial clinical hold raises questions on safety and creates near term uncertainty.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $3.27 and its highest was $29.03 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Currently, no data Available
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is 137 days ago.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on May 07, 2024. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.767 by $0.907.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -$0.84.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 71,013,230 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.767. Following the earnings report the stock price went up 5.034%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Among the largest hedge funds holding Zentalis Pharmaceuticals’s share is Matrix Capital Management Company, LP. It holds Zentalis Pharmaceuticals’s shares valued at 220M.
---
Zentalis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.70 (168.84% Upside)
$10.70 (168.84% Upside)
Blogger Sentiment
Bullish
ZNTL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 174.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.44%
12-Months-Change
Fundamentals
Return on Equity
-51.86%
Trailing 12-Months
Asset Growth
13.92%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.
---
ZNTL Stock 12 Month Forecast
Average Price Target
$10.70
▲(168.84% Upside)
Technical Analysis
Best Analysts Covering ZNTL
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-47.67%
reiterated a buy rating 6 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.67% per trade.
---